Aims Patients with heart failure and preserved ejection fraction (HFpEF) frequently have
difficult-to-control hypertension. We examined the effect of neprilysin inhibition on 'apparent …

Background Resistant hypertension is a salt‐retaining condition possibly attributable to
inappropriate aldosterone secretion. Methods and Results This study was a secondary …

Aims The TITRATION trial investigated two strategies to initiate and up‐titrate
sacubitril/valsartan (LCZ696) to the same target dose, over a condensed (3‐week) or …

Abstract Objectives: The PARAGON-HF (Prospective Comparison of ARNI with ARB Global
Outcomes in HF With Preserved Ejection Fraction) trial is designed to determine the efficacy …

Background: To describe the baseline characteristics of patients with heart failure and
preserved left ventricular ejection fraction enrolled in the PARAGON-HF trial (Prospective …

Background: In PARADIGM-HF (Prospective Comparison of Angiotensin Receptor
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …

Background Guidelines recommend targeting systolic blood pressure (SBP)< 130 mm Hg in
heart failure with preserved ejection fraction (HFpEF) with limited data. Objectives This study …

Background: While disease-modifying therapies exist for heart failure (HF) with reduced left
ventricular ejection fraction (LVEF), few options are available for patients in the higher range …

Background The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a
reduced risk of hospitalization for heart failure or death from cardiovascular causes among …

Background Angiotensin receptor and neprilysin inhibition (ARNI) has been shown to
reduce cardiovascular mortality by 20% as compared with enalapril in a randomized …